NEWS & UPDATES
Stay informed on the healthcare industry, capital markets, and corporate transactions. Get the latest on financing, M&A, strategic partnerships, and industry developments.
China's biopharma sector recorded a sharp rebound in September 2026, with reported primary-market financing reaching $8.05 billion and out-licensing deals highlighting continued global demand for Chinese drug innovation.
Read More →
Sandoz and Shanghai Henlius Biotech have entered into a license agreement for three biosimilars, with Sandoz gaining commercialization rights outside of China. This collaboration highlights the trend of Chinese biopharmaceutical companies leveraging license-out deals to connect with global commercialization networks.
Read More →
Shanghai RAAS plans to acquire 100% of Boehringer Ingelheim Biologics (China) Co., Ltd. This transaction involves the integration of innovative drug commercialization and production, biologics capacity, and R&D systems, reflecting a shift in the logic of healthcare M&A from simple asset expansion to the integration of R&D, production, and commercialization capabilities.
Read More →
In August 2026, several listed medical device companies adjusted their industrial layout through equity acquisitions, establishment of subsidiaries, and other means. The direction of capital operations includes both the integration of main businesses and the extension into high-value-added medical technologies and new business areas.
Read More →
In the first half of 2026, overseas licensing deals for China's innovative drugs remained active. Industry data shows that Chinese companies participated in the majority of large-scale global innovative drug licensing transactions. Cross-border BD, license-out, and international commercialization are becoming important development directions for China's healthcare industry.
Read More →
T-Capital was awarded the title of 'Top 50 China Healthcare Industry - Value Investment and Service Institutions' for 2026 by vcbeat.net. This industry recognition reflects T-Capital's long-term practice in transaction services, capital resource connection, and enterprise value empowerment in the healthcare sector.
Read More →
Interventional ultrasound imaging platform company Bingjing Intelligent has completed two consecutive rounds of financing, with a total amount of nearly 100 million yuan. T-Capital served as the financial advisor for the relevant financing rounds. This article introduces Bingjing Intelligent's interventional ultrasound technology platform, full-chain independent research and development capabilities, product commercialization progress, and domestic development path.
Read More →
Guangzhou Deep Medical Technology Co., Ltd. has completed its Series A financing with investment from Kangjun Capital. This funding will support the FUNZAR microsurgery robot's progression through clinical trials, product registration, and expansion into domestic and international markets.
Read More →
Thanks to its continuous deep dive and transaction service performance in the healthcare sector, T-Capital was awarded the 'Healthcare Financial Advisor of the Year' at the VBDATA 2025 Future Healthcare 100 Awards, reflecting T-Capital's sustained expertise in healthcare investment, financing, and capital transaction services.
Read More →
Beijing Yuewei Medical has completed a nearly CNY 100 million Series A++ financing, exclusively invested by the Beijing Medical and Health Industry Investment Fund. This round of funding will be primarily used for the research and development of innovative devices for the entire process of coronary heart disease diagnosis and treatment, a pulsatile left ventricular assist system, and the market promotion of its already approved and marketed products.
Read More →
Yangguang Anjin has completed a Pre-A round financing of over CNY 100 million, led by Qiming Venture Partners, with participation from BioTrack Capital and Tsing-Yuan Capital. This round of financing will be used for the preclinical and early clinical development of its pain treatment R&D pipeline, accelerating the R&D of small molecule innovative drugs targeting sodium ion channels such as Nav1.8.
Read More →
Thanks to its continuous deep dive and project service performance in the healthcare sector, T-Capital was selected as one of the Top 3 Financial Advisors in China's Healthcare Sector for 2023 by Qiming片, and was also included in the Best Financial Advisor Comprehensive List and the Most Active Financial Advisor List.
Read More →